Aurora Cannabis Denounces Second False Investing.com Article

Ticker: ACB · Form: 6-K · Filed: 2025-06-20T00:00:00.000Z

Sentiment: neutral

Topics: news-release, legal-dispute, company-statement

Related Tickers: ACB

TL;DR

ACB says Investing.com published another fake article, telling investors to ignore it.

AI Summary

Aurora Cannabis Inc. (ACB) issued a Form 6-K on June 20, 2025, to report a news release dated June 19, 2025. The news release addresses a second false article published by Investing.com concerning the company. Aurora Cannabis is advising its shareholders and potential investors to disregard the information presented in the Investing.com article.

Why It Matters

This filing indicates potential reputational damage and market manipulation concerns for Aurora Cannabis, as it actively refutes negative press from a financial news outlet.

Risk Assessment

Risk Level: medium — The company is responding to potentially damaging false information, which could impact investor sentiment and stock price.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose is to report a news release dated June 19, 2025, which addresses a second false article published by Investing.com.

Who is identified as the publisher of the false articles?

Investing.com is identified as the publisher of the false articles.

What action is Aurora Cannabis advising its stakeholders to take regarding the Investing.com article?

Aurora Cannabis is advising its shareholders and potential investors to disregard the information presented in the Investing.com article.

Who signed the Form 6-K on behalf of Aurora Cannabis Inc.?

Miguel Martin, Chief Executive Officer, signed the Form 6-K.

What is the filing date of this Form 6-K?

The filing date of this Form 6-K is June 20, 2025.

From the Filing

0001279569-25-000645.txt : 20250620 0001279569-25-000645.hdr.sgml : 20250620 20250620064616 ACCESSION NUMBER: 0001279569-25-000645 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250619 FILED AS OF DATE: 20250620 DATE AS OF CHANGE: 20250620 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 251059025 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 aurora_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☐ Form 40-F ☒ SUBMITTED HEREWITH Exhibits Description 99.1 News release dated June 19, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Miguel Martin Miguel Martin Chief Executive Officer Date: June 19, 2025 EX-99.1 2 ex991.htm NEWS RELEASE DATED JUNE 19, 2025 Exhibit 99.1 Aurora Cannabis Advises of Second False Article from Investing.com NASDAQ | TSX: ACB EDMONTON, AB, June 19, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora" ) (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, has become aware of a second instance of misinformation posted on news website, Investing.com. On June 18, 2025, Aurora advised the market that an article posted on Investing.com incorrectly stated that Aurora had agreed to acquire New Zealand-based MedLeaf Therapeutics. Later in the day on June 18, 2025, a second article was posted on Investing.com that incorrectly states that Aurora has entered into a strategic partnership with MediPharm GmbH for distribution of medical cannabis in Germany and other EU markets. The Company categorically denies both Investing.com articles. Aurora has not entered into any such agreements, has had no discussions with MedLeaf Therapeutics or MediPharm GmbH with respect to any business combination transaction or strategic partnership, and has not made any statements or filed any information pertaining to any such transactions. The erroneous articles posted on Investing.com state that they were generated "with the support of AI" and reviewed by an editor. The Company is launching an investigation into the genesis of these articles. In the meantime, Aurora confirms that it is not in possession of material non-public information and advises investors that Investing.com should not be considered a credible source of information regarding the Company. Any information regarding material corporate transactions will be announced directly by the Company to the market as soon as it is appropriate to do so. About Aurora Cannabis Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Speci

View on Read The Filing